CRISPR Therapeutics (CRSP) Stock Looks Fairly Valued Despite Pipeline Promise

CRISPR Therapeutics has delivered a steep share price decline of about 64.9% over the past 5 years, yet on broad valuation checks the stock now looks closer to fairly valued than like a clear bargain or clear bubble.

• The roughly 64.9% slide over 5 years highlights how much long term shareholders have given up in returns, which naturally raises the bar for any new investment case.
• Progress on CRISPR Therapeutics' allogeneic CAR-T programs, including the Phase 1 work on CTX112 aimed at off the shelf treatments for lymphoma and autoimmune diseases, can support higher valuation expectations, while clinical, regulatory and execution risks around these therapies may weigh on how much investors are willing to pay.
• On Simply Wall St's broader checks, CRISPR Therapeutics scores 3 out of 6 for value, which points to a mixed picture rather than a stock that screens clearly cheap or clearly expensive.

The issue now is whether CRISPR Therapeutics' current price already reflects a fair balance between those long term setbacks and the potential of its gene editing pipeline, or if there is still a meaningful gap between expectations and what investors are paying.

Find out why CRISPR Therapeutics' -14.4% return over the last year is lagging behind its peers.

Where Does CRISPR Therapeutics Sit on Book Value?

P/B is a useful anchor for CRISPR Therapeutics because it is still in the loss making, research heavy stage where book value and cash matter more than earnings.

CRISPR Therapeutics currently trades at a P/B of about 2.6x, which is close to the biotech industry average of roughly 2.4x and well below the peer group average of about 7.3x. That suggests investors are paying a modest premium to the sector’s balance sheet valuation, but not the richer multiples seen for some higher profile or more fully funded peers.

Despite attention on CRISPR Therapeutics' CAR T ambitions and the large market being discussed in recent coverage, the P/B multiple still points to a stock that is broadly in line with sector norms rather than priced for extreme outcomes.

On the P/B multiple alone, CRISPR Therapeutics appears roughly fairly valued against its biotech peers.

See what the numbers say about this price — find out in our valuation breakdown.

The CRISPR Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for CRISPR Therapeutics pick up from this valuation puzzle and spell out which paths for revenue, margins and earnings would need to play out for the stock to be worth a lot more or a lot less than today’s price, and they sit on the company’s Community page. Rather than relying on a single multiple or model, each Narrative lays out its own fair value assumptions so you can compare them with CRISPR Therapeutics' actual results over time.

Share a Narrative on CRISPR Therapeutics to add your voice to the Simply Wall St community and present a clear, number-driven case on whether its push into allogeneic CAR T therapies and the targeted US$60b CAR T market is reflected in the current share price.

This is a way to set out your view in one place and track how it holds up as CRISPR Therapeutics' clinical results, funding decisions and competitive position change over time.

Do you think there's more to the story for CRISPR Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

For CRISPR Therapeutics, the valuation work mostly points to a stock that now sits close to the middle of the road rather than at a clear discount or premium. Current market multiples suggest investors are giving some credit for the gene editing and CAR T pipeline, but not paying up for very optimistic outcomes. From here, the key question is whether the company can convert its research efforts into durable products without eroding that balance sheet support, since progress on that front is what is likely to decide whether the current pricing proves cautious or generous.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com